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Glucocorticoid resistance of 
migration and gene expression in 
a daughter MDA-MB-231 breast 
tumour cell line selected for high 
metastatic potential
Ebony R. Fietz1,*, Christine R. Keenan1,*, Guillermo López-Campos2, Yan Tu1, 
Cameron N. Johnstone3, Trudi Harris1 & Alastair G. Stewart1
Glucocorticoids are commonly used to prevent chemotherapy-induced nausea and vomiting despite 
a lack of understanding of their direct effect on cancer progression. Recent studies suggest that 
glucocorticoids inhibit cancer cell migration. However, this action has not been investigated in estrogen 
receptor (ER)-negative breast tumour cells, although activation of the glucocorticoid receptor (GR) is 
associated with a worse prognosis in ER-negative breast cancers. In this study we have explored the 
effect of glucocorticoids on the migration of the ER-negative MDA-MB-231 human breast tumour cell 
line and the highly metastatic MDA-MB-231-HM.LNm5 cell line that was generated through  
in vivo cycling. We show for the first time that glucocorticoids inhibit 2- and 3-dimensional migration 
of MDA-MB-231 cells. Selection of cells for high metastatic potential resulted in a less migratory cell 
phenotype that was resistant to regulation by glucocorticoids and showed decreased GR receptor 
expression. The emergence of glucocorticoid resistance during metastatic selection may partly explain 
the apparent disparity between the clinical and in vitro evidence regarding the actions of glucocorticoids 
in cancer. These findings highlight the highly plastic nature of tumour cells, and underscore the need 
to more fully understand the direct effect of glucocorticoid treatment on different stages of metastatic 
progression.
Glucocorticoids are used extensively and best known as anti-inflammatory and immunosuppressive agents. 
However, over 30 years ago, the glucocorticoid dexamethasone was reported to be effective in preventing 
chemotherapy-induced nausea and vomiting1,2. Since that time, glucocorticoids have also been shown to pre-
vent postoperative3,4 and radiotherapy-induced5 nausea and vomiting. Thus, glucocorticoids constitute one of the 
major classes of drugs that are considered first-line anti-emetic agents, together with 5HT3 receptor antagonists, 
such as ondansetron, tachykinin NK1 receptor antagonists, such as aprepitant, and dopamine D2 receptor antag-
onists, such as metoclopramide6. Despite the common use of glucocorticoids as anti-emetics in cancer patients 
receiving chemotherapy, the mechanism of action of this effect remains unclear. Several mechanisms have been 
proposed7 including: decreasing the inflammatory response from chemotherapy or radiation8–10; direct actions 
on the solitary tract nucleus in the central nervous system which receives emetogenic inputs from the afferent 
sympathetic and parasympathetic nervous systems11; effects on key mediators/receptors in emetic pathways such 
as 5HT and NK receptors12–14; and effects on the hypothalamic-pituitary-adrenal (HPA)-axis15. Rapid glucocor-
ticoid actions related to increased levels of endocannabinoid CB1 ligands may also play a role in the antiemetic 
effect of glucocorticoids16,17. Furthermore, there is a surprising lack of characterisation of the direct effect of 
glucocorticoids on the development and progression of different cancers.
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At a molecular level, glucocorticoids act through the glucocorticoid receptor (GRα , herein referred to as 
GR) and predominantly work by modulating gene transcription, although non-genomic mechanisms are 
increasingly being reported18. In the absence of ligand, the GR is principally located in the cytoplasm in an inac-
tive multi-protein complex19. Upon ligand binding, the GR undergoes a conformational change whereby the 
complexed proteins dissociate and nuclear localisation signals are exposed, promoting rapid nuclear translo-
cation. Once in the nucleus, the ligand-bound GR is able to: initiate transactivation of genes containing glu-
cocorticoid response elements (GREs); repress transcription of genes containing a negative GRE (nGRE); and 
trans-repress the activity of other transcription factors such as activator protein-1 (AP-1) and nuclear factor 
kappa B (NF-κ B)20,21. The number of genes modulated by glucocorticoid administration varies depending on cell 
type and context20,21. However, in some circumstances over 10% of the entire genome can be regulated following 
a single dose of glucocorticoid22.
Breast cancer is the second most common cancer worldwide, and the most common cancer in females23. 
Breast cancer mortality is primarily due to metastatic spread of the tumour to secondary sites, such as bone and 
lung. Functional GR is expressed in almost all cell types, including breast tumour cells and the surrounding 
stromal tissue24,25, highlighting the imperative to understand what direct effects glucocorticoid use may have 
on breast tumour cell biology. Unlike in lymphoid cells where glucocorticoids cause cell death, glucocorticoids 
inhibit apoptosis of epithelial cell types26 including breast tumour cells27. This promotion of cell survival has 
been proposed to interfere with the cytotoxic effects of chemotherapy28,29, although there is a lack of clinical 
studies to support this idea30. Glucocorticoids may also decrease cell invasion by reducing tissue permeability31. 
Importantly, activation of the GR has been shown to be associated with a worse prognosis in estrogen receptor 
(ER)-negative breast cancer32,33. This is particularly significant, since ER-negative tumours are often intrinsically 
more metastatic than ER-positive tumours34. Furthermore, few treatment or prevention strategies are availa-
ble for patients with ER-negative breast cancer35. Recent studies have shown that glucocorticoids can inhibit 
migration of neuronal precursor cells36, A549 lung adenocarcinoma cells37, MCF10A breast epithelial cells38, and 
estrogen-receptor positive T47D breast cancer cells39. However, the effect of glucocorticoids on estrogen-receptor 
negative breast tumour cell migration is yet to be established.
In this study, we have explored the effect of glucocorticoids on the migration of the ER-negative MDA-MB-231 
human breast tumour cell line. Cell migration is a critical component of metastasis, allowing cells to intravasate 
and travel via the circulation to seed in secondary organs, forming metastases. We have therefore also examined 
the changes in migratory phenotype and glucocorticoid sensitivity that occur following selection of cells with 
high metastatic potential, using the MDA-MB-231-HM.LNm5 cell line. This cell line was generated by in vivo 
passaging of tumour cells which has been demonstrated to be a useful method to select for highly metastatic cell 
lines40.
Results
Glucocorticoids inhibit the migration of the ER-negative MDA-MB-231 human breast tumour 
cells. Fetal calf serum at a sub-maximal concentration of 1% (Supplementary Figure S1) was used as a stimulus 
for MDA-MB-231 cell migration in the scrape wound healing assay (Fig. 1A). Dexamethasone concentration-de-
pendently inhibited FCS-induced MDA-MB-231 cell migration with complete inhibition observed at 10 nM Dex 
(Fig. 1B). Dexamethasone at 100 nM had no effect on cell proliferation as measured by direct cell enumeration 
and by the resazurin assay (Supplementary Figure S2). Other glucocorticoids, including methylprednisolone 
(100 nM), budesonide (100 nM) and hydrocortisone (1 μ M), similarly inhibited MDA-MB-231 cell migration 
(Fig. 1C). Furthermore, dexamethasone fully inhibited the migration of the non-invasive ER-positive MCF-7 
breast tumour cell line (Fig. 1D).
Glucocorticoids inhibit 3-dimensional MDA-MB-231 human breast tumour cell migration and 
invasion. Dexamethasone inhibited both chemotactic and chemokinetic migration (induced by 1% FCS) 
in the modified Boyden chamber assay (Fig. 1E). The chemotactic and chemokinetic migratory effects of FCS 
were enhanced when the Transwell inserts were coated with Matrigel™ (Fig. 1F). However, this enhanced migra-
tion remained sensitive to attenuation by dexamethasone (Fig. 1F). Dexamethasone also slowed the basal and 
FCS-stimulated matrix invasion of MDA-MB-231 cells in a 3-dimensional cell-spheroid based assay (Fig. 2).
Glucocorticoid inhibition of MDA-MB-231 cell migration is sensitive to the GR antagonist 
RU486 and the protein synthesis inhibitor cycloheximide. The GR transactivation antagonist and 
transrepression partial agonist RU486 (1 μ M) had no effect on FCS-induced cell migration, but completely pre-
vented the inhibition caused by dexamethasone (Fig. 3A). This concentration of RU486 was sufficient to fully 
inhibit GRE transactivation by dexamethasone in a reporter assay system (Fig. 3B).
In order to determine whether de novo protein synthesis was required for the inhibition of cell migration, cells 
were incubated with cycloheximide for 1 h prior to dexamethasone addition. Due to the capacity of cyclohex-
imide to influence cell migration per se, higher concentrations of FCS were employed to generate a positive migra-
tion stimulus (Supplementary Figure S3). The extent of dexamethasone-induced inhibition of cell migration was 
decreased in the presence of cycloheximide over all the FCS concentrations used (Fig. 3C).
Glucocorticoid inhibition of MDA-MB-231 cell migration is not mediated by a secreted product. 
Given cycloheximide attenuated the glucocorticoid inhibition of migration, the synthesis of new protein prod-
ucts is required to manifest the anti-migratory effect. We therefore next investigated whether a newly formed 
anti-migratory protein may be released from glucocorticoid-treated cells and act in an autocrine or paracrine 
manner to inhibit cell migration. As expected, conditioned medium from dexamethasone-treated cells inhibited 
FCS-induced migration of naïve cells (Fig. 3D). However, when RU486 was added to block the activity of the 
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Figure 1. Effect of glucocorticoids on 2-dimensional migration of ER-negative MDA-MB-231 and ER-positive 
MCF-7 breast tumour cells. Serum-starved MDA-MB-231 cells (A,B,C) and MCF-7 cells (D) were scrape-wounded 
and then pre-incubated with glucocorticoids (dexamethasone, Dex; hydrocortisone, HC; methylprednisolone, MP; 
budesonide, Bud) for 30 min prior to the addition of FCS (1% v/v) to promote cell migration. Wound infiltration 
was measured by the change in grey-value using ImageJ/FIJI software (A). The extent of wound closure 15 h after 
FCS addition is expressed as a percentage of basal and presented as mean ± SEM of n = 4 independent experiments. 
Chemotactic and chemokinetic migration of serum-stared MDA-MB-231 cells was observed using uncoated  
(E) and Matrigel™ -coated (F) transwell inserts in a modified Boyden chamber assay. Dexamethasone was added to 
both compartments 30 min before FCS (1% v/v) that was added to both compartments to stimulate chemokinetic 
migration, or bottom compartment only to stimulate chemotactic migration. After 20 h, migrated cells were 
stained using Diff-Quick™ and visualised by light microscopy at a magnification of 400× . Data are expressed as the 
number of migrated cells per high powered field (HPF, 400× ) and presented as mean ± SEM of n = 3 independent 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001 from repeated measures one-way ANOVA with Dunnett’s post-hoc 
test (B,C) or two-way ANOVA with Bonferroni post-hoc test (D,E,F).
www.nature.com/scientificreports/
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dexamethasone in the conditioned-medium, the FCS-induced migration was not influenced by the conditioned 
medium (Fig. 3D). These results suggest no stable anti-migratory mediator is released by MDA-MB-231 cells in 
response to 4 hours of dexamethasone treatment.
MDA-MB-231HM.LNm5 breast cancer cells are spontaneously metastatic to lymph node, liver 
and lung in immuno-compromised mice. The metastatic capacity of MDA-MB-231HM.LNm5 cells was 
compared with that of parental MDA-MB-231 cells in immuno-compromised NSG mice using in vivo and ex vivo 
imaging. MDA-MB-231HM.LNm5 cells spontaneously metastasised to liver, lung and axillary lymph nodes in 
all three mice inoculated (Supplementary Figure S4, Table S1). In addition, spleen metastases were also observed 
in one mouse while large paraspinal metastases between the kidneys were evident in two animals. Notably, the 
extent of metastasis to liver, lung, and lymph node appeared independent of local tumour recurrence following 
surgical resection of the primary tumour. Distant metastasis was not evident in mice inoculated with parental 
MDA-MB-231 cells (data not shown).
MDA-MB-231-HM.LNm5 cells show decreased cell migration and decreased glucocorticoid 
sensitivity compared to parental MDA-MB-231 cells. The highly metastatic MDA-MB-231-HM.
LNm5 cell line showed reduced basal migration in the scrape wound healing assay compared to the parental line 
(Fig. 4A). FCS (1%) enhanced wound closure in both the highly metastatic MDA-MB-231-HM.LNm5 cell line 
and in the parental cell line. Remarkably, dexamethasone influenced neither basal migration, nor FCS-induced 
Figure 2. Effect of glucocorticoids on collagen matrix invasion of 3-dimensional MDA-MB-231 cell 
spheroids. 3-dimensional MDA-MB-231 cell spheroids were generated in low-adhesion round bottom 96 well 
plates then embedded into type-I fibrillar collagen derived from rat-tails (450 μ g/mL). Collagen-embedded 
spheroids were then treated with dexamethasone (100 nM) or vehicle control (0.01% DMSO) for 30 min prior 
to the addition of fetal calf serum (FCS, 5% v/v). Static images were taken every 24 hours for 96 h total using 
an Olympus IX51 microscope (A). The cell-containing area was traced using ImageJ software to determine the 
extent of invasion (B). Data are expressed as the area of invasion in pixels/1000 and presented as mean ± SEM 
from n = 8 independent experiments. *P < 0.05, ***P < 0.001 from two-way ANOVA with Bonferroni post-hoc 
test.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:43774 | DOI: 10.1038/srep43774
migration in the highly metastatic variant (Fig. 4A). Similar observations were made in the Boyden chamber 
assay, where the highly metastatic variant showed reduced FCS-induced migration and no effect of dexametha-
sone treatment (Fig. 4B). In the 3D spheroid invasion assay, the highly metastatic variant cell line showed similar 
levels of collagen invasion to the parental cell line (Fig. 4C). However, no effect of dexamethasone on MDA-MB-
231-HM.LNm5 collagen invasion was observed (Fig. 4C).
MDA-MB-231-HM.LNm5 cells show decreased glucocorticoid receptor expression and 
decreased glucocorticoid-responsive gene expression compared to parental MDA-MB-231 
cells. Upon examination by qPCR, GR expression was significantly lower in MDA-MB-231-HM.LNm5 cells 
compared to parental cells (Fig. 5). There was also reduced expression of the dexamethasone-responsive genes 
encoding glucocorticoid-induced leucine zipper (GILZ, gene name TSC22D3) and epithelial sodium channel 1 
alpha (ENaCα , gene name SCNN1A) (Fig. 5).
Gene Ontology enrichment analysis identifies the most highly enriched gene ontologies relate 
to cell motility and migration in dexamethasone-treated MDA-MB-231 cells compared to 
MDA-MB-231-HM.LNm5 cells. Transcriptomic analysis of the parental and MDA-MB-231-HM.LNm5 
cells detected 10352 genes above threshold levels of 10 cpm. A hierarchical list of differentially expressed genes 
between the Dex-treated MDA-MB-231 and MDA-MB-231-HM.LNm5 cell lines were subject to Gene Ontology 
(GO) enrichment analysis and 9703 genes were found to be associated with a GO term. Dex-treated parental 
MDA-MB-231 cells were found to have 199 enriched ontologies (p < 0.001) compared to Dex-treated MDA-MB-
231-HM.LNm5 cells (Supplementary Figure S5A). Of these, the 8 most enriched ontologies (p < 10−10) all relate 
to locomotion and migration (Table 1, Supplementary Figure S5B).
Figure 3. Glucocorticoid inhibition of MDA-MB-231 cell migration is sensitive to the GR antagonist 
RU486 and the protein synthesis inhibitor cycloheximide, but does not involve a secreted mediator. 
Glucocorticoid receptor antagonist RU486 prevents dexamethasone (10 nM) inhibition of wound closure 
(A) at a concentration that fully inhibits pGRE-SEAP reporter construct activation (B). The extent of wound 
closure 15 h after FCS addition is expressed as a percentage of basal (A) and the extent of pGRE-SEAP 
activation is expressed as relative light units (RLU) from a chemiluminescence SEAP detection kit (B). The 
protein synthesis inhibitor cycloheximide also attenuates dexamethasone inhibition of cell migration (C). 
To account for differences in extent of migration from different FCS concentrations, results are expressed as 
percentage inhibition of wound closure (C). Dexamethasone-conditioned medium (4 h exposure) in which 
the glucocorticoid activity is prevented by RU486 does not influence cell migration in scrape wound healing 
assay (D). All data are presented as mean ± SEM of n = 3 independent experiments. *P < 0.05, **P < 0.01, 
***P < 0.001 from two-way ANOVA with Bonferroni post-hoc test.
www.nature.com/scientificreports/
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MDA-MB-231-HM.LNm5 cell transcriptome shows decreased dexamethasone-induced 
changes in migratory genes compared to parental MDA-MB-231 cell transcriptome. Further 
transcriptomic analysis was performed on dexamethasone-induced changes in migratory genes by examining the 
magnitude of change of Dex over control for genes directly annotated with GO terms positive regulation of cell 
migration” (GO:0030335) and “negative regulation of cell migration” (GO:0030336).
Parental and MDA-MB-231-HM.LNm5 cells revealed the detectable expression of 233 genes annotated with 
the term “positive regulation of cell migration” (GO:0030335). Of these 233 genes, 78 genes were regulated by 
dexamethasone in either cell line (Fig. 6A). Of the 36 genes annotated with the term “positive regulation of cell 
migration” that were repressed to less than 0.66 fold by dexamethasone in the parental cell line (Fig. 6A, cluster 
1, 3, 4), 15 were repressed to a lesser extent (Fig. 6A, cluster 4) and 3 were stimulated (Fig. 6A, cluster 1) in the 
MDA-MB-231-HM.LNm5 cells. Of the 24 genes annotated with the term “positive regulation of cell migration” 
Figure 4. Effect of dexamethasone on migration of the highly metastatic MDA-MB-231-HM.LNm5 cell 
line. Migration of parental MDA-MB-231 and highly metastatic MDA-MB-231-HM.LNm5 cell line derived 
from lymph node metastasis of MDA-MB-231 cells were compared in scrape wound healing assay (A), modified 
Boyden chamber assay (B) and spheroid matrix invasion assay (C). Dexamethasone (100 nM) was added for 
30 min prior to stimulation with 1% v/v FCS (A,B) or 5% v/v FCS (C). Data are presented as mean ± SEM for 
n = 3 (A), n = 3–7 (B), n = 4 (C) independent experiments. *P < 0.05, ***P < 0.001 from two-way ANOVA with 
Bonferroni post-hoc test.
www.nature.com/scientificreports/
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which were stimulated by ≥ 1.5 fold by dexamethasone in the parental cell line (Fig. 6A, cluster 5 & 6), 9 were 
repressed to a lesser extent (Fig. 6A, cluster 6) and 5 were repressed (Fig. 6A, cluster 5) in the MDA-MB-231-HM.
LNm5 cells. 9 genes (Fig. 6A, cluster 7) were only induced in the MDA-MB-231-HM.LNm5 cell line and not in 
the parental cell line.
128 genes annotated with the term “negative regulation of cell migration” (GO:0030336) were detected in the 
RNA-Seq analysis above threshold levels as specified in the methods section. Of these, 33 genes were regulated 
by dexamethasone in either the parental or MDA-MB-231-HM.LNm5 cell line (Fig. 6B). 2 genes were selectively 
induced in the parental line (Fig. 6B, cluster 1) and 5 genes were selectively induced in the MDA-MB-231-HM.
LNm5 cell line (Fig. 6B, cluster 3). In contrast, 3 genes were selectively repressed in the parental line (Fig. 6B, 
cluster 4) and 7 genes were selectively repressed in the MDA-MB-231-HM.LNm5 cell line (Fig. 6B, cluster 6).
Discussion and Conclusions
This work has shown for the first time that glucocorticoids inhibit 2- and 3-dimensional migration of the 
ER-negative MDA-MB-231 human breast cancer cell line. This study has added to the growing body of evidence 
that glucocorticoids inhibit cell migration36–39. We found similar inhibitory effects in ER-positive MCF-7 and 
ER-negative MDA-MB-231 breast tumour cells suggesting that the presence of the ER is not permissive for the 
anti-migratory effects of dexamethasone, despite a known connection between the ER and cellular migration41 
and the fact that ER-negative tumours are often intrinsically more metastatic than ER-positive tumours34.
Given cellular migration is a critical component of metastasis, we also examined the changes in migratory 
phenotype and glucocorticoid sensitivity that occur during selection of cells with high metastatic potential. The 
highly metastatic MDA-MB-231-HM.LNm5 cell line showed decreased basal and FCS-induced migration and, 
surprisingly, glucocorticoid treatment of this cell line caused no inhibition of migration. We therefore conclude 
that selection for high metastatic potential has resulted in a less migratory cell phenotype and a decreased respon-
siveness to the anti-migratory effect of glucocorticoids.
The observation that the highly metastatic cell line has decreased migratory phenotype is unexpected 
although not entirely unprecedented, as inverse relationships between migratory behaviour and metastasis have 
been previously observed in melanoma42. This finding highlights the complex nature of metastasis whereby cells 
do not merely acquire a pro-migratory and pro-invasive phenotype but also become highly proliferative, evade 
apoptotic mechanisms, become insensitive to anti-growth signals, promote sustained angiogenesis and develop 
a limitless replicating potential43. Our results might suggest that the metastatic selection was driven by a change 
Figure 5. Glucocorticoid receptor and glucocorticoid-inducible gene expression in highly metastatic 
MDA-MB-231-HM.LNm5 cell line compared with parental MDA-MB-231 cells. qPCR was performed on 
cDNA derived from highly metastatic MDA-MB-231-HM.LNm5 cells and parental MDA-MB-231 cells treated 
with dexamethasone for 24 h. Target gene expression of glucocorticoid receptor (GRα ; gene name: NR3C1), 
epithelial sodium channel alpha subunit (ENaCα ; gene name: SCNN1A), glucocorticoid inducible leucine 
zipper (GILZ; gene name: TSC22D3) was normalised to 18 S rRNA housekeeping gene and is expressed as 
fold-change from levels in parental MDA control cells. Data presented as mean ± SEM from n = 4 independent 
experiments. *P < 0.05, **P < 0.01 from two-way ANOVA with Bonferroni post-hoc test.
GO term Description P-value FDR q-value Fold enrichment
GO:0051272 positive regulation of cellular component movement 2.62 × 10−11 3.24 × 10−7 3.16
GO:0040017 positive regulation of locomotion 3.25 × 10−11 2.01 × 10−7 3.09
GO:2000147 positive regulation of cell motility 4.03 × 10−11 1.67 × 10−7 3.18
GO:0040012 regulation of locomotion 2.18 × 10−10 6.77 × 10−7 2.79
GO:0030334 regulation of cell migration 2.27 × 10−10 5.64 × 10−7 2.54
GO:0051270 regulation of cellular component movement 2.46 × 10−10 5.08 × 10−7 2.90
GO:2000145 regulation of cell motility 3.22 × 10−10 5.70 × 10−7 2.96
GO:0030335 positive regulation of cell migration 3.35 × 10−10 5.19 × 10−7 3.08
Table 1.  Highly enriched gene ontologies ascertained through GOrilla analysis of RNA-seq experiment 
comparing Dexamethasone treated MDA-MB-231 and MDA-MB-231-HM.LNm5 cells.
www.nature.com/scientificreports/
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in one or more of these other mechanisms, and the resulting effect on migration was secondary to these changes. 
Alternatively the decrease in migratory phenotype may have promoted the metastatic phenotype by allowing 
cells more time to adhere and grow at metastatic sites, or may have facilitated evasion of immune recognition 
mechanisms.
Interestingly, the sensitivity of MDA-MB-231 cells to glucocorticoid treatment was altered by the selection for 
metastatic potential. MDA-MB-231-HM.LNm5 cells showed no change in cell migration or invasion upon treat-
ment with dexamethasone. We also found that the MDA-MB-231-HM.LNm5 cell line expresses much lower lev-
els of GRalpha mRNA and this correlated with reduced dexamethasone-induction of glucocorticoid-responsive 
genes. The emergent resistance to the actions of glucocorticoids through metastatic selection is to our knowledge 
a novel finding. Importantly, it was not a result of selection pressure following drug administration, since the 
in vivo cycling method40,44 used to generate the highly metastatic cell line did not expose the cells to high levels of 
glucocorticoid, but rather the resistance occurs against a physiological background concentration of corticoster-
one. Our data also suggest that the decrease in GRalpha and concomitant decrease in glucocorticoid sensitivity 
may be permissive to the establishment of the more metastatic phenotype. For example, glucocorticoids are well 
known to be anti-angiogenic45, through both direct effects on endothelial cells46, as well as through suppression 
Figure 6. Dexamethasone-induced changes in migratory genes in the transcriptomes of MDA-MB-
231-HM.LNm5 and parental MDA-MB-231 cell lines. RNA-Seq analysis was performed on dexamethasone-
treated and control MDA-MB-231-HM.LNm5 and parental MDA-MB-231 cell lines. Dex-induced changes in 
expression of genes annotated with (A) GO:0030335 ‘positive regulation of cell migration’ or (B) GO:0030336 
‘negative regulation of cell migration’ in the amiGO Gene Ontology (GO) database were calculated as log2(fold 
change, FC, of Dex/Control) for each cell line. Genes with low read count (< 10 cpm in all samples) or low Dex 
regulation (< 1.5 fold) were excluded from the analysis. The remaining genes were hierarchically clustered 
using an uncentered correlation as distance measure and an average linkage using Cluster 3.0 software and 
are presented as heat maps generated by java TreeView. Clusters of genes showing a similar pattern of Dex-
regulation have been numbered 1–7 for GO:0030335 and 1–6 for GO:0030336.
www.nature.com/scientificreports/
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of angiogenic factor release from cells neighbouring the vasculature, including tumour cells47. It is therefore 
intriguing to speculate that a reduction in glucocorticoid sensitivity has promoted the release of pro-angiogenic 
mediators from the MDA-MB-231-HM.LNm5 cell line, causing an increase in metastatic potential through an 
increase in angiogenesis.
Several steps in this study have been taken to ensure that migratory responses rather than cellular proliferation 
were assessed. Several distinct assays of migration assessed: movement of tumour cells as 2-dimensional cellu-
lar monolayers; individual cell migration through transwell pores in the presence and absence of extracellular 
matrix; as well as invasion in 3-dimensions through extracellular matrix. These separate approaches allowed us 
to increase our confidence in our conclusions. Each experiment was carefully designed to use minimal FCS con-
centrations to stimulate migration and we have kept the duration of experiments as short as possible in order to 
minimise the contribution of proliferation. Despite these precautions, it was still necessary to directly assess the 
influence of dexamethasone exposure on MDA-MB-231 cell proliferation. As expected, FCS stimulation caused 
an increase in proliferation as measured by both cell enumeration and Resazurin assay. However, dexamethasone 
exposure had no effect on basal or FCS-stimulated cell number in either assay. We therefore interpret the gluco-
corticoid influences on cell migration as direct rather than secondary to changes in cell number.
The inhibition of migration by glucocorticoids in the parental MDA-MB-231 cell line was completely pre-
vented by the GR antagonist RU486, suggesting that this effect is mediated through canonical GR transactivation 
signalling mechanisms48. The glucocorticoid effect required production of new protein products, as evidenced 
by reduced inhibition in the presence of cycloheximide. This observation ruled out non-genomic mechanisms 
of glucocorticoid actions, such as modulation of PI3K and JNK signalling pathways18,20. However, there was no 
evidence of mediation by a secreted product. Further work will be required to determine the precise mechanism 
through which GR transactivation leads to inhibition of migration. However, this could be difficult to establish due 
to the multitude of inter-dependent GR mechanisms20,21,49. Interestingly, we found distinct transcriptomic patterns 
between the highly metastatic and parental cell lines following dexamethasone treatment in genes controlling both 
positive and negative regulation of migration. This suggests that selection for metastatic potential has resulted in 
altered glucocorticoid signalling mechanisms and an impaired ability to activate pathways leading to inhibition 
of migration. Interestingly, different glucocorticoids have recently been shown to differentially activate the tran-
scription of different genes products50 foreshadowing future drug optimisation strategies for improved efficacy49 
in attenuating cell migration. Importantly, since the discovery of the anti-emetic effect of glucocorticoids in the 
early 1980 s, there has been little or no optimisation for this indication. It remains likely that certain glucocorticoid 
agonists have better efficacy/safety profiles than those currently used (dexamethasone or methylprednisolone).
In this study, we have presented evidence that the sensitivity of MDA-MB-231 breast tumour cells to dex-
amethasone is dependent on the stage of metastatic progression. We do not yet know what molecular altera-
tions have occurred during the phenotype change from parental MDA-MB-231 cell line to the highly metastatic 
MDA-MB-231-HM.LNm5 cell line. Nor do we know at what stage of metastatic phenotype selection the resist-
ance to glucocorticoid inhibition emerged. In future work it will also be important to establish whether other sim-
ilar sublines express similar characteristics following metastatic selection since the current study is limited to one 
cell line. Importantly, the emergence of glucocorticoid resistance during metastatic selection may go some way to 
explaining the apparent disparity between clinical evidence that activation of the GR is associated with a worse 
prognosis in estrogen receptor (ER)-negative breast cancer32,33, and in vitro studies showing inhibitory actions 
of glucocorticoids in commonly used cell lines. These findings highlight the highly plastic nature of tumour cells 
during metastasis, and underscore the need to more fully understand the direct effect of adjuvant glucocorticoid 
treatment on cancer cell biology at different stages of progression.
Methods
Cell Culture. MDA-MB-231 and MCF-7 breast tumour cells (ATCC, Manassas, VA, USA) were cultured in 
phenol-red free RPMI 1640 and DMEM respectively supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (FCS), 2 mM L-glutamine, 1 mM nonessential amino acids, 1 mM sodium pyruvate, 15 mM HEPES 
solution, 100 U/mL penicillin and 100 μ g/mL streptomycin as previously described51,52. The highly metastatic 
MDA-MB-231-HM.LNm5 cell line was generated through a two-step process whereby a cell population initially 
selected by 6 cycles of transplanting spontaneous MDA-MB-231 pulmonary metastases to the mammary fat 
pad44 (designated MDA-MB-231-HM and kindly provided by ZM Shao and ZL Ou (Breast Cancer Institute, 
Fudan University, Shanghai, China) were inoculated into the mammary fat pad of a female BALB/c-SCID mouse, 
following which the axillary lymph node metastases were isolated. All experiments involving mice had approval 
from the Peter MacCallum Animal Experimentation Ethics Committee and were carried out in accordance with 
the Australian code for the care and use of animals for scientific purposes (8th edition, 2013). MDA-MB-231-HM.
LNm5 cells were cultured in RPMI 1640 supplemented as above.
Assessment of metastatic potential. The metastatic capacity of MDA-MB-231HM.LNm5 cells was 
compared with that of parental MDA-MB-231 cells in immuno-compromised NOD scid gamma (NSG) mice. 
To facilitate optical imaging of tumours in vivo, both parental MDA-MB-231 and MDA-MB-231HM cells were 
transduced with retrovirus encoding tdTomato fluorescent protein, selected with Blasticidin S and bulk sorted for 
tdTomato expression by flow cytometry (FACSAria, Beckton Dickinson) as previously described53. Both popula-
tions were also transduced with retrovirus encoding Firefly luciferase and selected using puromycin53. Cells (n = 3 
for each line) were inoculated into the 4th inguinal mammary gland of NSG mice and tumours were allowed to 
form (one tumour per mouse). Primary mammary tumours were surgically resected 22 days after inoculation. 
In vivo bioluminescence imaging was performed 13 days after primary tumour resection to detect 
luciferase-positive proximal metastatic lesions. Mice were culled 21 days following resection and distant 
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metastases were evaluated by ex vivo imaging of tdTomato fluorescence in whole organs (lung, liver, spine, lymph 
node and spleen) using fluorescent stereomicroscopy.
Scrape wound healing assay. MDA-MB-231 cells were subcultured in 24-well plates at a density of 
105 cells/cm2 and grown in serum-containing media until confluency was reached before being starved for 
24 hours in serum-free media containing 0.25% BSA. A sterile 200 μ L pipette tip was used to scrape away a central 
portion of cells and media was replaced to remove dislodged cells and debris. Cells were treated with glucocor-
ticoids (1–100 nM dexamethasone, 1 μ M hydrocortisone, 100 nM methylprednisolone, 100 nM budesonide) for 
30 minutes prior to stimulation with FCS (0.1–5%). The concentrations of glucocorticoids used are able to fully 
saturate the glucocorticoid receptor and show maximal effects in a wide variety of cell types including airway 
smooth muscle cells54, airway epithelial cells50, breast cancer cells55, peripheral blood mononuclear cells56. In 
selected experiments, GR antagonist 1 μ M RU486 was added 30 min prior to glucocorticoids. Protein synthesis 
inhibitor cycloheximide (1 μ M) was added 1 h prior to glucocorticoids. Conditioned media was generated by 
exposing confluent, serum-starved MDA-MB-231 cells to dexamethasone or vehicle for 4 hours before media was 
transferred to a denuded 24-well plate and treatments added as above. Cells were imaged every 30 minutes for 
15 hours using the Leica DMI6000B live cell imaging microscope, being maintained at 37 °C in an atmosphere of 
room air containing 5% CO2. The optical density (grey value) of the denuded region was determined by manual 
delineation of the wound area using ImageJ (version 1.46). This value was subtracted from the grey values of the 
same area in subsequent frames. In individual experiments, the wound closure at 15 hours in untreated (control) 
culture was used to normalise all other values.
Boyden chamber assay. Chemotactic and chemokinetic migration was observed using polycarbonate 
cell culture inserts containing 8 μ m pores (Costar #3422). Some inserts were coated with 7 μ L Matrigel™ (BD 
Biosciences, North Ryde, NSW, Australia), diluted 1:3 with serum-free RPMI to assess cell invasion. Inserts were 
centrifuged for 10 minutes at 270 g to generate an even coating. MDA-MB-231 cells grown to confluence in 25 cm2 
flasks were serum-starved for 24 h then dislodged using trypsin-EDTA. 50,000 cells in 150 μ l serum-free RPMI 
were seeded into the upper compartment of cell culture inserts and left to adhere for 6 h with 500 μ l serum-free 
RPMI in the bottom compartment. 100 nM dexamethasone was added to both compartments 30 min before 
FCS (1% v/v) was added to stimulate chemokinetic migration (FCS added to both compartments) or chemo-
tactic migration (FCS added to bottom compartment only). Inserts were incubated for 20 hours at 37 °C in 5% 
CO2 at which time non-migrated cells were scraped from the upper side of the polycarbonate membrane and 
migrated cells on the underside of the membrane were stained using Diff-Quick™ (Thermo Fisher, Scoresby, 
VIC, Australia). Briefly, inserts were washed twice with PBS, fixed with DiffQuick™ fix for 2 min then stained in 
DiffQuick™ red stain for 10 seconds, followed by DiffQuick™ blue for 6 seconds, and then washed twice in PBS. 
Membranes were excised from inserts using a scalpel, placed onto microscope slides to air dry and coverslipped 
using DEPEX mountant. Cells were visualised by light microscopy at a magnification of 400× . The number of 
cells was counted, with five central, adjacent fields of view averaged for each insert.
3D spheroid matrix invasion assay. Round bottom 96-well plates (Corning, Tewksbury, MA, USA) were 
coated with 0.5% poly(2-hydroxyethyl methacrylate) (poly-HEMA) to minimise cell adhesion. Cell spheroids 
were generated in 96 h from 5,000 cells which were seeded into each poly-HEMA coated well in a non-gel form-
ing concentration (2.5%) of Cultrex® extracellular matrix (R&D Systems, Minneapolis, USA) in RPMI medium.
Spheroid matrix invasion was assessed by embedding cell spheroids in type-I fibrillar collagen derived from 
rat-tails (450 μ g/mL). The spheroid-containing collagen was incubated at 37 °C for 1 hour to allow the collagen 
to set before 100 μ L serum-free RPMI was added along with dexamethasone (100 nM) or vehicle (0.01% DMSO) 
for 30 minutes prior to the addition of FCS (5%). Static images of the spheroids were taken every 24 hours using 
an Olympus IX51 microscope. The cell-containing area was traced using ImageJ software to determine the extent 
of invasion.
pGRE-SEAP reporter assay. MDA-MB-231 cells were transiently transfected with a pGRE-SEAP reporter 
construct (Clontech, Mountain View, CA, USA) as previously described57. Briefly, cells were transfected for 
6 hours with a pGRE-SEAP reporter construct (150 ng/well) that was complexed with Lipofectamine 2000 rea-
gent (1 μ L/well) in 100 μ L/well of OptiMEM for 20 min at room temperature prior to addition to cells. The day 
after transfection, cells were treated with RU486 (1 μ M) for 30 min prior to glucocorticoid stimulation. After 24 h, 
supernatants were collected and the amount of secreted human placental alkaline phosphatase (SEAP) was deter-
mined using a chemiluminescence kit (Roche Applied Science, NSW, Australia).
RNA extraction and RT-qPCR. MDA-MB-231 and MDA-MB-231-HM.LNm5 cells were subcultured into 
24-well plates at 105 cells/cm2 and grown for 48 hours before being serum-starved for 24 h. Cells were treated with 
dexamethasone (100 nM) for 24 hours before total RNA was harvested using TRIzol® (Life technologies). Reverse 
transcription was carried out using the High Capacity cDNA Reverse Transcription Kit (Invitrogen, Mulgrave, 
VIC, Australia). Reactions of 5 μ L total volume were performed using 2 μ l total RNA (containing 100 ng RNA), 
2.5 μ L 2× RT Buffer, 0.25 μ L 20× RT Enzyme Mix and 0.25 μ L DEPC-treated water. Thermal conditions for 
the reaction were 37 °C, 60 minutes; 95 °C, 5 minutes which was performed on a Mastercycler® Pro (Eppendorf, 
Hamburg, Germany). The resulting cDNA was diluted with 145 μ L DEPC-treated water and stored at −20 °C. 
Real-time PCR was performed in triplicate for each gene of interest in a 384-well plate using ABI Prism 7900HT 
sequence detection system (Applied Biosystems). Each 5 μ L reaction consisted of 1.5 μ L diluted cDNA, 2.5 μ L 
iTaq™ universal SYBR® Green Supermix (Bio Rad, Gladesville, NSW, Australia) and 0.5 μ L of each of the relevant 
forward and reverse primers (Table 2). The conditions for PCR amplification were: 50 °C for 2 min then 95 °C for 
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10 min followed by 40 cycles of 95 °C for 0.15 min, and 60 °C for 1 min. The threshold cycle determined for each 
gene was normalized against that obtained for 18S ribosomal RNA, which was measured as internal control.
Cell enumeration. MDA-MB-231 cells were subcultured in 24-well plates at a density of 50,000 cells/cm2 
and grown in serum-containing media for 24 hours before being starved for 24 hours in serum-free media con-
taining 0.25% BSA. Cells were treated with 100 nM dexamethasone for 30 min prior to stimulation with FCS 5% 
for 48 hours. Cells were then exposed to 0.12% (w/v) trypsin for 5 minutes before being neutralised in a 0.067% 
Trypan blue/FCS solution. The number of cells per well was then manually counted using a haemocytometer in 
duplicate.
Resazurin reduction assay. Reduction of the redox dye resazurin to resorufin was used as a measure of 
cellular proliferation58. MDA-MB-231 cells were seeded in 96 well flat-bottomed plates at 36,000 cells/cm2 and 
allowed to adhere/proliferate for 24 hours before being starved for 24 hours in serum-free RPMI. Cells were 
pre-incubated with 100 nM dexamethasone for 30 min before stimulation with 1–5% (v/v) FCS for 48 h. Medium 
was aspirated and cells were incubated with resazurin reagent containing 1.5% (w/v) Resazurin, 0.25 (w/v) meth-
ylene blue, 2.9% (w/v) potassium hexacyanoferrate (III) and 4.22% (w/v) potassium hexacyanoferrate (II) trihy-
drate for 2 h at 37˚C in 5% CO2. Resorufin formation was measured fluorometrically at excitation of 570 nm and 
emission of 620 nm using a FlexStationIII (Molecular Devices, Sunnyvale, CA, USA).
Transcriptomic Analysis. MDA-MB-231 and MDA-MB-231-HM.LNm5 cells were serum-starved for 24 h 
then treated with dexamethasone (100 nM) or vehicle control for 24 hours after which total RNA was extracted 
using TRIzol® (as above). RNA-Seq libraries were prepared from 500 ng total RNA using NEBNext Ultra RNA 
library prep kit for Illumina (#E7530) with NEBNext Poly(A) mRNA Magnetic Isolation Module (#E7490). 
Prior to library preparation, RNA was confirmed to be of high quality (RIN > 8) by Agilent Bioanalyzer 2100 
analysis. Paired end 2 × 50 bp rapid sequencing was performed on an Illumina HiSeq 2500 in the Melbourne 
Translational Genomic Platform, University of Melbourne. Raw data was filtered by removing reads with adaptor 
sequences, reads where the percentage of unknown bases is greater than 10%, and reads considered low quality 
(where bases with quality value less than or equal to 5 constitute greater than 50% of base reads) to obtain clean 
reads. All subsequent analyses are based on clean reads only. Clean reads were mapped to the human refer-
ence genome GRCh38-hg38 assembly using Rsubread package59. Reads that were aligned to annotated coding 
regions of the genome were counted using featureCounts60 and gene expression values were calculated for each 
gene as counts per million (cpm). Genes that did not reach a threshold level of 10 cpm in at least one condition 
were excluded from further analysis. Gene Ontology (GO) enrichment analysis was performed using GOrilla61,62 
(http://cbl-gorilla.cs.technion.ac.il) on a hierarchical list of differentially expressed genes between the Dex-treated 
MDA-MB-231 and MDA-MB-231-HM.LNm5 cell lines. Further GO annotation analysis was carried out on 
genes annotated with GO:0030335 ‘positive regulation of migration’ and GO:0030336 ‘negative regulation of 
migration’ according to the AmiGO 2 database (version 2.3.2). For this analysis, Dex-induced changes were cal-
culated as log2(fold change, FC) of Dex over Control for each cell line. We then performed hierarchical clustering 
using an uncentred correlation as distance measure and an average linkage using Cluster 3.0 software (http://
bonsai.ims.utokyo.ac.jp/~mdehoon/software/cluster) and visualized clustered Heat maps using java TreeView 
(http://jtreeview.sourceforge.net).
Statistical analysis. Results are expressed at mean ± SEM from n independent experiments (performed 
on separate days on cells from a different passage) and analysed as grouped data. Scrape wound healing is 
expressed as a percentage of the total control migration observed over 15 hours. Modified Boyden chamber data 
are expressed as the number of migrated cells per high-powered field (average of 5 fields). pGRE-SEAP activity 
data are expressed as relative light units. Quantitative PCR data are expressed as the fold change in expression 
from control. Cell viability data are expressed as a percentage of the number of control cells counted. One-way 
or Two-way ANOVA with repeated measures was performed using GraphPad Prism 5.0 on non-normalised data 
(GraphPad, San Diego, CA, USA). Post hoc Dunnett’s and Bonferroni tests were then performed to ascertain sig-
nificance. P < 0.05 was considered to be statistically significant.
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